Amarantus Bioscience acquires option to license Alzheimer's IP of Dr. Arendt Amarantus Bioscience announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3rd Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development. Dr. Arendt has filed international patent applications on the concepts of modulating the expression of P16 in the brains of patients of Alzheimer's disease using gene therapy. P16 is a cell cycle protein that assists in maintaining and nurturing synaptic connections that is hypothesized to be at the root of Alzheimer's pathology. The company is currently developing an Alzheimer's blood diagnostic LymPro Test capable of identifying cell cycle dysregulation by harvesting peripheral blood lymphocytes. This option agreement opens the possibility of a targeted therapeutic on those Alzheimer's patients that have tested positive for LymPro.
Amarantus Bioscience's LymPro test confirms biomarkers for Alzheimer's Amarantus BioScience reported positive top-line results of its LP-002 study of the Lymphocyte Proliferation Test blood diagnostic for Alzheimer's disease. Results from the 140-subject study demonstrated that multiple individual biomarkers achieved statistically significant results to correctly identify patients with AD from healthy controls. Biomarker services using LymPro Test biomarker data are now available to the pharmaceutical industry for Investigational Use Only. In addition, the company identified a new, undisclosed biomarker that correlates with AD diagnosis and could become a central component of a multivariate algorithm currently being analyzed by company scientists to deliver a simplified assessment of an individual's likelihood of having Alzheimer's disease. Each of the three stages of Alzheimer's disease showed significant differences in marker expression as compared to healthy controls. In addition, after further analysis of a 44 subject 7-year longitudinal retrospective study, LymPro was able to distinguish Alzheimer's disease from Parkinson's and vascular dementias with a sensitivity of 94% and specificity of 65%.